The Companies announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
The Company announced plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016.
Attend our Emerging Therapeutic Technologies CE sessions on osteoarthritis and post-operative pain management, inappetence and osteosarcoma at the American Animal Hospital Association Conference 2016.
At the Western Veterinary Conference 2016, Aratana sponsored 12 scientific CE sessions and interacted with thousands of veterinary professionals at their exhibit booth to introduce the emerging therapeutics they are bringing to the market.
Today the Company announced the Company submitted an administrative New Animal Drug Application (NADA) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for appetite stimulation for dogs.
Today the Company announced the Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved a therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs.
Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
Attend our Emerging Therapeutic Technologies CE sessions on Tuesday, March 8 and Wednesday, March 9 to discover novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
The Aratana CE dinner program was an informative evening for VOS attendees. On the evening of February 29 in Big Sky, Montana, conference attendees learned about new therapeutics in development for their patients from Aratana.
The Company plans to present at the Barclays Capital Global Healthcare Conference on Wednesday, March 16 at 3:50 p.m. ET in Miami at the Loews Miami Beach Hotel.
VOS meeting attendees are invited to the Aratana CE dinner program to learn about new therapeutic solutions in development for their patients.
The Company received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic for appetite stimulation in dogs.
The Company will host a live conference call on Tuesday, March 15, 2016 at 8:30 a.m. ET to discuss financial results for the fourth quarter ending December 31, 2015 and the full year.
The Company received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) for a therapeutic to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.
The Company has filed a Marketing Authorization Application with the European Medicines Agency (EMA) for a therapeutic intended to treat pain and inflammation in dogs with osteoarthritis.
Discover how we’re working to raise the standard of care with novel therapeutics in development for osteoarthritis, post-operative pain, inappetence, lymphoma and osteosarcoma.
Aratana made a strong connection with nearly 1,000 veterinary professionals at their sponsored, main event. Dr. Steven St. Peter opened the event with an introduction to Aratana and introduced the authors of the New York Times best selling book, Zoobiquity: The Astonishing Connection Between Human and Animal Health.